×
About 1,800 results
AZASITE® (azithromomycin)
http://azasite.com/hcp/overview.html?hcpUser=yes

Read about product information, request product samples, and order coupons for eligible patients for AzaSite.

BESIVANCE® (besifloxacin ophthalmic suspension)
http://bausch.com/ecp/our-products/rx-pharmaceuticals/rx-pharmaceuticals/besivance-ecp

Indication. BESIVANCE (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, ...

Elitek (rasburicase) IV Infusion | Healthcare Professional Site
https://www.elitekpro.com/

The official HCP site for Elitek (rasburicase) for the initial management of plasma uric acid levels in adults and pediatric patients. See trial design, and Important Safety Information, including Boxed WARNING.

LASTACAFT® (alcaftadine ophthalmic solution) 0.25%
https://www.lastacaft.com/

With LASTACAFT® ophthalmic solution, just one drop, once a day, helps prevent your ... LASTACAFT® ophthalmic solution blocks the release of histamine from ...

ISTALOL® (timolol maleate ophthalmic solution)
http://www.bausch.com/our-products/rx-pharmaceutical/istalol-timolol-maleate-ophthalmic-solution-05

In a well controlled, double-masked, parallel study of 332 patients with untreated intraocular pressures of 22 mm Hg or greater, Istalol administered once daily (AM) was equivalent to timolol maleate ophthalmic solution 0.5% administered twice daily.1 In both groups, mean intraocular pressure decreased from 25 mm Hg at ...

LUMIGAN® (bimatoprost ophthalmic solution)
http://www.lumigan.com/

LUMIGAN® 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Nivestym™ (filgrastim-aafi)
https://www.pfizerpro.com/product/nivestym/hcp

See risks and benefits. Nivestym™ (filgrastim-aafi) is a biosimilar of NEUPOGEN® (filgrastim). Read more about the indications and info on biosimilars. Keywords: acute myeloid leukemia, neutropenia, idopathic neutropenia, leukemias

PATADAY (olopatadine hydrochloride ophthalmic solution) SOLUTION
http://www.pro.pataday.com/

PATADAY™ solution is a mast cell stabilizer indicated for the treatment of ocular itching associated with allergic conjunctivitis.

PAZEO (olopatadine hydrochloride ophthalmic solution)
http://www.pazeohcp.com/

PAZEO™ solution is a mast cell stabilizer indicated for the treatment of ocular itching associated with allergic conjunctivitis.

COMBIGAN® (brimonidine tartrate/timolol maleate ophthalmic solution)
https://www.combigan.com/hcp/

COMBIGAN® is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

EYLEA® (aflibercept) INJECTION
https://hcp.eylea.us/

The official website to learn more about EYLEA (aflibercept) Injection for Wet AMD, MEfRVO, DME, and DR in DME. See safety and risk information.

ILUVIEN® (fluocinolone acetonide intravitreal implant)
http://iluvien.com/hcp/

Indication. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is an implant injected into the eye (vitreous) and used for the treatment of diabetic macular edema (DME) in patients who have been treated with corticosteroids before and did not have a significant increase in eye pressure.

LUCENTIS® (ranibizumab injection)
http://www.lucentis.com/hcp.html

Find important information about LUCENTIS® (ranibizumab injection) specifically tailored for healthcare professionals here. INDICATIONS LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with: Neovascular (wet) age-related macular degeneration (wAMD) Macular edema following retinal vein ...

ALPHAGAN® P (brimonidine tartrate ophthalmic solution)
http://alphaganp.com/hcp/siteindex.aspx

ALPHAGAN ® P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

ALREX® (loteprednol etabonate ophthalmic suspension)
http://www.bausch.com/ecp/our-products/rx-pharmaceuticals/rx-pharmaceuticals/alrex-loteprednol-etabonate-ophthalmic-suspension-02

Alrex ophthalmic suspension (loteprednol etabonate ophthalmic suspension) 0.2% is indicated for temporary relief of the signs and symptoms of seasonal allergic conjunctivitis. ... Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic ...

AZOPT® (brinzolamide ophthalmic suspension) 1%
http://www.myglaucomasupport.com/explore-treatments/azopt-suspension.shtml

AZOPT ® Suspension is a carbonic anhydrase inhibitor (CAI) indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or ...

BEPREVE® (bepotastine besilate ophthalmic solution)
http://bausch.com/ecp/our-products/rx-pharmaceuticals/rx-pharmaceuticals/bepreve/

BEPREVE (bepotastine besilate ophthalmic solution) 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.

COSOPT® PF (dorzolamide hydrochloride-timolol maleate ophthalmic solution)
http://www.akorn.com/prod_detail.php?ndc=17478-604-30

COSOPT PF is a carbonic anhydrase inhibitor with a beta-adrenergic receptor blocking agent indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers.

BOTOX® (onabotulinumtoxinA)
https://www.botoxmedical.com/

Access exclusive BOTOX® training resources and learn about BOTOX® indications. See full safety and Prescribing Information including Boxed Warning.

RHOPRESSA® (netarsudil ophthalmic solution)
https://rhopressa.com/hcp/

Rhopressa (netarsudil ophthalmic solution) 0.02% is a once-daily Rho-associated protein kinase (ROCK) inhibitor approved by the FDA for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. See full Prescribing and Safety Information.